Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data and Trends in Adverse Drug Reactions

Capa
Jeffrey K. Aronson
Elsevier, 19/08/2011 - 714 páginas
The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then, as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of Adverse Drug Reactions and Interactions. An international team of specialists has contributed to the Annuals by selecting critically from each year's writing all that is truly new and informative, by critically interpreting it, and by pointing to whatever is misleading.
  • Provides a critical yearly survey of new data and trends
  • Includes an essay that describes the modern approach to classifying adverse drug reactions
  • Special reviews in this Annual include, among other topics: Antipsychotic drugs and now-onset diabetes mellitus, Treating asthma during pregnancy, and MMR vaccine and autism

No interior do livro

Opinião das pessoas - Escrever uma crítica

Não foram encontradas quaisquer críticas nos locais habituais.

Índice

Chapter 28 Antiprotozoal drugs
294
Chapter 29 Antiviral drugs
300
Chapter 30 Drugs used in tuberculosis and leprosy
315
Chapter 31 Antihelminthic drugs
320
Chapter 32 Vaccines
327
Chapter 33 Blood blood components plasma and plasma products
338
Chapter 34 Formulations used in nutrition
353
Chapter 35 Drugs affecting blood coagulation fibrinolysis and hemostasis
358

Chapter 9 Antiinflammatory and antipyretic analgesics and drugs used in gout
116
Chapter 10 General anesthetics and therapeutic gases
128
Chapter 11 Local anesthetics
135
Chapter 12 Neuromuscular blocking agents and skeletal muscle relaxants
145
Chapter 13 Drugs that affect autonomic functions or the extrapyramidal system
148
Chapter 14 Dermatological drugs topical agents and cosmetics
156
Chapter 15 Antihistamines H1 receptor antagonists
161
Chapter 16 Drugs acting on the respiratory tract
168
Chapter 17 Positive inotropic drugs and drugs used in dysrhythmias
182
Chapter 18 Betaadrenoceptor antagonists and antianginal drugs
194
Chapter 19 Drugs acting on the cerebral and peripheral circulations
202
Chapter 20 Antihypertensive drugs
206
Chapter 21 Diuretics
219
Chapter 22 Metals
225
Chapter 23 Metal antagonists
235
Chapter 24 Antiseptic drugs and disinfectants
241
Chapter 25 Penicillins cephalosporins other betalactam antibiotics and tetracyclines
244
Chapter 26 Miscellaneous antibacterial drugs
253
Chapter 27 Antifungal drugs
280
Chapter 36 Gastrointestinal drugs
371
cytokines and monoclonal antibodies
383
immunosuppressive and immunostimulatory drugs
424
Chapter 39 Corticotrophins corticosteroids and prostaglandins
480
Chapter 40 Sex hormones and related compounds including hormonal contraceptives
493
Chapter 41 Thyroid hormones and antithyroid drugs
520
Chapter 42 Insulin other hypoglycemic drugs and glucagon
523
Chapter 43 Miscellaneous hormones
539
Chapter 44 Drugs that affect lipid metabolism
546
Chapter 45 Cytostatic drugs
551
Chapter 46 Radiological contrast agents
573
Chapter 47 Drugs used in ocular treatment
581
Chapter 48 Treatments used in complementary and alternative medicine
583
Chapter 49 Miscellaneous drugs and materials medical devices and techniques
596
Address list of national centres that participate in the WHO Drug Monitoring Programme
618
Index of drugs
632
Index of adverse effects
644
Direitos de autor

Outras edições - Ver tudo

Palavras e frases frequentes

Passagens conhecidas

Página 193 - ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology /American Heart Association Task Force on Practice guidelines (Committee on Management of Acute Myocardial Infarction).
Página 126 - Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
Página 127 - CAPRIE Steering Committee. A randomised. blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE).
Página 313 - Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States.
Página 184 - Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus.
Página 184 - C Risk cannot be ruled out. Human studies are lacking, and animal studies are either positive for fetal risk, or lacking as well. However, potential benefits may justify the potential risk.
Página 127 - Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.
Página 477 - Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22(5):909-18.
Página xxxiv - Reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Usually more than a single report is required to generate a signal, depending on the seriousness of the event and the quality of the information.

Acerca do autor (2011)

Dr Jeffrey K. Aronson is a consultant clinical pharmacologist and physician in the Department of Primary Health Care in the University of Oxford and a consultant physician in the Oxford Radcliffe Hospitals Trust. He has been associated with the Meyler series since 1977 and has published many research papers on adverse drug reactions. He is President of the British Pharmacological Society and serves on many committees concerned with drug therapy, including the Technology Appraisal Committee of the UK’s National Institute for Health and Clinical Excellence (NICE) and the Joint Formulary Committees of the British National Formulary and the British National Formulary for Children.

Informação bibliográfica